Clinical reality in CML is in constant change. Thanks to the hard work and progress of clinicians and researchers worldwide, interesting updates on CML science, diagnostics, treatment and care are regularly presented at international meetings and published in leading peer-reviewed journals.
This section provides you with a selection of scientific publications on CML, relevant news from scientific meetings and expert opinions from leaders in the field. You will also find links to active CML clinical trials.
Guidance from hepatologists suggests patients with CML on TKI therapy and HBV should receive antivirals and that viral load should be monitored. However, there are mixed messages in the literature and guidelines and clear practical guidance on screening and monitoring for HBV in these patients is lacking. Most hematology centres have very few CML patients who are Hepatitis B positive and therefore again, experience and practical guidance for HBV reactivation for people also being treated for CML is limited.
On the initiative of Professor Dragana Milojkovic (Imperial College London, UK), the iCMLf has formed a HBV and CML Working Group*. This group will collect and collate global experiences of physicians treating CML and HBV with the aim of developing recommendations on monitoring and treatment of HBV for patients with CML.
The iCMLf Hepatitis B virus (HBV) Screening and Management Survey is now open.
Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:
Clinical CML papers
Scientific CML papers
European Hematology Association (EHA) 2024 Hybrid Congress
13-16 June, 2024 - Madrid
Click here to access the EHA Library and find oral presentations, e-Posters and abstracts on CML:
Search here for CML clinical trials:
Page 1 of 2